European Organisation For Research & Treatment Of Cancer
🇬🇧United Kingdom
Clinical Trials
349
Active:25
Completed:187
Trial Phases
4 Phases
Phase 1:34
Phase 2:146
Phase 3:128
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (322 trials with phase data)• Click on a phase to view related trials
Phase 2
146 (45.3%)Phase 3
128 (39.8%)Phase 1
34 (10.6%)Not Applicable
13 (4.0%)phase_2_3
1 (0.3%)Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study
Not Applicable
Not yet recruiting
- Conditions
- Non-Muscle Invasive Bladder Cancer
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Target Recruit Count
- 50
- Registration Number
- NCT06990061
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
Phase 1
Not yet recruiting
- Conditions
- GastroEsophageal Cancer
- Interventions
- Drug: FLOT
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-06-05
- Target Recruit Count
- 27
- Registration Number
- NCT06978062
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Phase 3
Not yet recruiting
- Conditions
- IDH-mutant Grade 2 or 3 Astrocytoma
- Interventions
- Drug: Vorasidenib Placebo
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 468
- Registration Number
- NCT06809322
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Austria
🇦🇹Kepler University Hospital - Neuromed campus, Linz, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-23
- Target Recruit Count
- 48
- Registration Number
- NCT06783348
OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)
Not Applicable
Not yet recruiting
- Conditions
- Colorectal CancerProstate CancerOligometastatic DiseaseBreast CancerNSCLC
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2025-02-26
- Target Recruit Count
- 302
- Registration Number
- NCT06462963
- Prev
- 1
- 2
- 3
- 4
- 5
- 70
- Next
News
No news found